Table 1.
Summary of m6A RNA modification in therapy resistant cancer cells.
| Sr No. | Resistance | Cancer | m6A regulator | Onco/tumor suppressor | Ref |
|---|---|---|---|---|---|
| 1 | Cisplatin | CSCC | FTO | Oncogene | (30) |
| 2 | Cisplatin | Nasopharyngeal | METTL3 | Oncogene | (28) |
| 3 | Cisplatin | NSCLC | METTL3 | Oncogene | (19) |
| 4 | Cisplatin | NSCLC | YTHDF1 | Tumor suppressor | (29) |
| 5 | Cisplatin | OSCC | ALKBH5 | Oncogene | (31) |
| 6 | Cisplatin | Pancreatic cancer | METTL3 | Oncogene | (38) |
| 7 | Cisplatin | NKTCL | WTAP | Oncogene | (61) |
| 8 | Cisplatin | Ovarian Cancer | YTHDF1 | Oncogene | (62) |
| 7 | oxaliplatin | Colorectal cancer | YTHDF1 | Oncogene | (39) |
| 9 | Doxorubicin | Osteosarcoma | m6A | Oncogene | (63) |
| 10 | Sorafenib | Hepatocellular carcinoma | METTL3 | Tumor suppressor | (34) |
| 11 | Sorafenib | hepatocellular carcinoma | m6A | Oncogene | (64) |
| 12 | Afatinib | NSCLC | m6A | Oncogene | (33) |
| 13 | Crizotinib | NSCLC | METTL3/WTAP | Oncogene | (65) |
| 14 | Gefitinib | NSCLC | METTL3 | Oncogene | (66) |
| 15 | 5-Fu | Pancreatic Cancer | METTL3 | Oncogene | (38) |
| 16 | 5-Fu | Colorectal cancer | YTHDF1 | Oncogene | (39) |
| 17 | Olaparib | Ovarian cancer | FTO/ALKBH5 | Oncogene | (46) |
| 18 | Everolimus | Gastric cancer | METTL3 | Tumor Suppressor | (67) |
| 17 | Tamoxifen | Breast Cancer | m6A | Oncogene | (68) |
| 19 | Y- Irradiation | GBM | METTL3 | Oncogene | (60) |
| 20 | Y- Irradiation | Pancreatic cancer | METTL3 | Oncogene | (38) |
| 21 | Y- Irradiation | CSCC | FTO | Oncogene | (30) |
| 22 | Anti PD1 | Melanoma | FTO/YTHDF2 | Oncogene | (55) |
| 23 | Anti PD1 | Melanoma/colorectal | ALKBH5 | Oncogene | (58) |
| 24 | PDL1 | HNSCC | m6A | Oncogene | (56) |